Get the Stockscreener App
2.43
4.29%
0.10
After Hours:
2.40
-0.03
-1.23%
Lipocine Inc stock is traded at $2.43, with a volume of 157.16K.
It is up +4.29% in the last 24 hours and up +25.26% over the past month.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
See More
Previous Close:
$2.33
Open:
$2.33
24h Volume:
157.16K
Relative Volume:
0.42
Market Cap:
$19.50M
Revenue:
$1.98M
Net Income/Loss:
$-9.63M
P/E Ratio:
-1.3765
EPS:
-1.7653
Net Cash Flow:
$-9.76M
1W Performance:
+6.11%
1M Performance:
+25.26%
6M Performance:
-7.95%
1Y Performance:
-26.77%
1-Day Range:
$2.33
$2.455
1-Week Range:
$2.25
$2.455
52-Week Range:
$1.81
$12.37
Lipocine Inc Stock (LPCN) Company Profile
Name
Lipocine Inc
Sector
Industry
Phone
801 994 7383
Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
2.43 | 18.70M | 1.98M | -9.63M | -9.76M | -1.7653 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-06-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-12-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-11-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| Dec-08-17 | Resumed | H.C. Wainwright | Buy |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
| Jun-23-15 | Initiated | Canaccord Genuity | Buy |
View All
Lipocine Inc Stock (LPCN) Latest News
MSN Money - MSN
Lipocine Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Lipocine stock plunges after LPCN 1154 misses phase 3 primary endpoint - MSN
LPCN stock crashes 78%—here’s why - MSN
Lipocine (LPCN) price target decreased by 45.45% to 6.12 - MSN
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session - Quantisnow
Lipocine (LPCN) price target decreased by 15.38% to 11.22 - MSN
LPCN (Lipocine Inc.) posts narrower Q4 2025 loss than analyst estimates, shares rise modestly in trading today.Put/Call Ratio - Cổng thông tin điện tử tỉnh Tây Ninh
Lipocine (LPCN) 2026 proxy seeks director votes and 1,000,000-share incentive plan - Stock Titan
Lipocine Reshapes Board Leadership Amid Strategic Shift - TipRanks
Board reshuffle at Lipocine (NASDAQ: LPCN) as chairman exits, new independent leader named - Stock Titan
What's going on with Lipocine stock on Monday? - MSN
Lipocine (LPCN) Stock: Investment Opportunity (Trend Weakens) 2026-04-18Pro Trader Recommendations - Xã Thanh Hà
A. G. P. Maintains Lipocine(LPCN.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
Quarterly Risk: What is the Moat Score of Lipocine IncMarket Growth Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
Is Lipocine (LPCN) Stock heavily shorted | Price at $2.03, Down 4.88%Catalyst Driven Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Higuchi John W. buys Lipocine (LPCN) shares worth $81199 - Investing.com UK
Higuchi John W. buys Lipocine (LPCN) shares worth $81199 By Investing.com - Investing.com India
Director John Higuchi adds 40,000 Lipocine (LPCN) shares at $2.03 - Stock Titan
Lipocine (NASDAQ:LPCN) CEO Mahesh Patel Acquires 25,000 Shares of Stock - Defense World
Higuchi John W. buys Lipocine (LPCN) shares worth $252,149 By Investing.com - Investing.com South Africa
CEO Mahesh Patel Increases Stake in Lipocine Inc with Recent Sha - GuruFocus
Higuchi John W. buys Lipocine (LPCN) shares worth $252,149 - Investing.com
Director John W. Higuchi buys 123K Lipocine (LPCN) shares at $2.05 - Stock Titan
Lipocine CEO Patel acquires $50,749 in LPCN stock - Investing.com UK
Lipocine CEO Patel acquires $50,749 in LPCN stock By Investing.com - Investing.com India
Lipocine (LPCN) CEO adds 25,000 shares in stock purchase - Stock Titan
Lipocine adds to PPD setbacks as Tepezza scores, batoclimab misses in TED - BioCentury
LPCN Downgraded to Neutral by HC Wainwright & Co. | LPCN Stock N - GuruFocus
Lipocine Inc Stock (LPCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):